iQone is a Swiss specialty pharma company for oncology, immunology and rare diseases. We commercialise innovative and biosimilar medicines with 7 marketed and 9 late-stage products. iQone can support partner products directly in the 5 major EU + CH markets, and indirectly in the rest of Europe. iQone Healthcare Switzerland was acquired by Celltrion in 2024.
Some insights
- Agility and speed of decision-making
- Pragmatism while delivering excellence
- High quality portfolio/pipeline boosting patient access to medicines for high unmet needs
Key strengths and skills that iQone currently focuses on and will continue to, are: